Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, USA.
Obstetrics and Gynecology, Southcentral Foundation, Anchorage, AK, USA.
Can J Gastroenterol Hepatol. 2019 Jun 2;2019:8654741. doi: 10.1155/2019/8654741. eCollection 2019.
Hepatitis C virus (HCV) infection in pregnant women is of concern as it presents a health threat not only to the mother, but also to her infant. A retrospective analysis was performed to evaluate HCV testing and exposure in women who delivered infants between 2013 and 2016 at a referral hospital in Alaska. Multiple risk behaviors were evaluated, including drug dependency or abuse (drug abuse), tobacco use, alcohol dependency or abuse, and late presentation to prenatal care. Of the 2856 women who delivered between 2013 and 2016, 470 (16.5%) were tested for HCV during pregnancy and 1356 (47.5%) were tested at any time prior to delivery (including pregnancy); 62 (2.2%) were positive for HCV antibodies. Of the 162 women with a documented history of drug abuse, 95 (58.6%) were tested for HCV during pregnancy and 143 (88.3%) were tested at any time prior to delivery (including pregnancy); 30 (18.5%) were positive for HCV antibodies. Forty-nine women (34%) with a documented history of drug abuse who were not previously known to be HCV positive were not tested for HCV during their pregnancy. In conclusion, approximately 2% of pregnant women in the study population were known to have been exposed to HCV by the time of their delivery. One-third of women with documented drug abuse did not have an HCV test during pregnancy, revealing gaps in HCV testing of pregnant women. Further studies are needed to understand the full costs and benefits of risk-based screening versus universal screening in this and other populations.
丙型肝炎病毒（HCV）感染在孕妇中令人担忧，因为它不仅对母亲，而且对其婴儿构成健康威胁。对阿拉斯加一家转诊医院 2013 年至 2016 年间分娩的妇女进行了 HCV 检测和暴露情况的回顾性分析。评估了多种风险行为，包括药物依赖或滥用（药物滥用）、吸烟、酒精依赖或滥用以及产前护理就诊时间晚。在 2013 年至 2016 年间分娩的 2856 名妇女中，470 名（16.5%）在怀孕期间接受了 HCV 检测，1356 名（47.5%）在分娩前的任何时候接受了检测（包括怀孕期间）；62 名（2.2%）HCV 抗体检测呈阳性。在有药物滥用病史记录的 162 名妇女中，95 名（58.6%）在怀孕期间接受了 HCV 检测，143 名（88.3%）在分娩前的任何时候接受了检测（包括怀孕期间）；30 名（18.5%）HCV 抗体检测呈阳性。49 名（34%）有药物滥用病史记录且先前未被认为是 HCV 阳性的妇女在怀孕期间未接受 HCV 检测。总之，研究人群中约有 2%的孕妇在分娩时已知接触过 HCV。三分之一有药物滥用病史记录的妇女在怀孕期间未接受 HCV 检测，这表明在孕妇中 HCV 检测存在漏洞。需要进一步研究以了解在该人群和其他人群中基于风险的筛查与普遍筛查的全部成本和效益。
